| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $4,155,549 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 000 | 4 | NIH | 12/15/2025 | $515,400 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA276360 | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer | 000 | 2 | NIH | 12/9/2025 | $173,016 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA295906 | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors | 000 | 2 | NIH | 12/19/2025 | $137,585 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA283514 | Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses | 000 | 2 | NIH | 12/11/2025 | $171,982 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122143 | Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | 000 | 5 | NIH | 12/19/2025 | $360,856 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS101880 | Molecular Determinants of Synaptic Plasticity in Chronic Pain | 000 | 9 | NIH | 12/10/2025 | $451,854 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295874 | Proteotoxic Metabolites in Genome Instability and Disease | 000 | 2 | NIH | 12/9/2025 | $519,032 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 3 | NIH | 12/11/2025 | $173,016 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 000 | 5 | NIH | 12/16/2025 | $448,597 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275990 | Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | 000 | 4 | NIH | 12/18/2025 | $529,259 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 000 | 4 | NIH | 12/15/2025 | $333,518 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 3 | NIH | 12/8/2025 | $468,540 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 3 | NIH | 12/17/2025 | $548,054 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255960 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients | 000 | 5 | NIH | 12/11/2025 | $428,160 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA271888 | Clinical Validation Center for Lung Cancer Early Detection | 000 | 4 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01FD008717 | Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity | 000 | 1 | FDA | 12/15/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01FD008717 | Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity | 000 | 1 | FDA | 12/15/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U54CA280804 | Center for Transformative Community-Driven Research to Prevent Obesity-related Cancer | 000 | 3 | NIH | 12/12/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286992 | Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types | 000 | 2 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273661 | A novel uterine leiomyosarcoma mouse model for therapeutic development | 000 | 2 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS119162 | New Therapeutic Approaches for Stratified High-REST GBM Subtype | 000 | 5 | NIH | 10/15/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA267856 | Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi) | 000 | 4 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 11/21/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247883 | Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | 000 | 5 | NIH | 11/24/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247862 | Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer | 000 | 5 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA248731 | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | 000 | 5 | NIH | 12/17/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA231509 | Pro-Drug Enolase Inhibitors in Precision Oncology | 000 | 5 | NIH | 12/17/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 3 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 000 | 10 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI183604 | Role of GRAIL in B cell tolerance and B-cell mediated inflammation | 000 | 1 | NIH | 11/27/2025 | -$657,643 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG067419 | Alzheimer's Disease Pathology in a Primate Model | 000 | 5 | NIH | 11/6/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P40OD024628 | Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR) | 000 | 8 | NIH | 12/8/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA281701 | The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer | 000 | 3 | NIH | 11/19/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA241651 | Development and Validation of a CSF Liquid Biopsy for Molecular Characterization and Monitoring of Patients with Central Nervous System Tumors | 000 | 6 | NIH | 12/18/2025 | -$27,752 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA237384 | Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis | 000 | 5 | NIH | 11/28/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA228304 | Crosstalk Between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer | 000 | 7 | NIH | 12/4/2025 | -$3,484 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA251703 | Identifying the vulnerabilities in Mdm2 overexpressing cancer cells | 000 | 5 | NIH | 12/9/2025 | -$2 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA243698 | Modeling tumor heterogeneity and treatment resistance in small cell lung cancer | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01AI156921 | Mitigating radiation-induced cardiovascular disease by inhibiting premature aging | 000 | 5 | NIH | 12/18/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DK108328 | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) | 000 | 10 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DK126365 | The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer | 000 | 5 | NIH | 11/25/2025 | -$28,407 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | UH3CA276603 | Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial | 000 | 2 | NIH | 11/21/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS116704 | Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment | 000 | 2 | NIH | 10/1/2025 | -$160,002 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251608 | A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously | 000 | 5 | NIH | 12/2/2025 | -$8,911 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251816 | Breaking down tumor immune privilege through targeted hypoxia reduction | 000 | 5 | NIH | 11/20/2025 | $0 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA224044 | Patient-Derived Models of Prostate Cancer for Personalized Medicine | 000 | 5 | NIH | 12/10/2025 | -$47,437 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01GM132219 | Building a Diverse Biomedical Workforce Through Communication Across Difference | 000 | 5 | NIH | 10/1/2025 | -$6,516 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA256136 | Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study | 000 | 2 | NIH | 11/28/2025 | -$39,634 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA256136 | Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study | 001 | 2 | NIH | 11/28/2025 | $39,634 |
|
